I am interested to submit one review article @genesndiseases.bsky.social . Tell me how to contact you

Great Women Leaders in Oncology (and allies) event last night at #asco25. Such energy in the room! @conquercancer.bsky.social @ascocancer.bsky.social @rachnatshroff.bsky.social

#asco25 President’s dinner at the Field Museum with @ascocancer.bsky.social presidents past and future - Lori Pierce & Beth Mittendorf @rachnatshroff.bsky.social

Supriya Peshin Announces Poster Acceptance on Colorectal Cancer at ESMO - OncoDaily Supriya Peshin Announces Poster Acceptance on Colorectal Cancer at ESMO / cancer, colorectal cancer, Deepak Vadehra, ESMO, Muhammad Awidi, OncoDaily,

Supriya Peshin Announces Poster Acceptance on Colorectal Cancer at ESMO
@supriyapeshin.bsky.social
@myesmo.bsky.social

oncodaily.com/blog/supriya...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ColorectalCancer #CRC #Poster

The best in #GIonc trials to look for at #ASCO25. 2⃣ plenary talks that will revolutionize #crcsm and #esocsm #stmcsm. Can't wait to take this best of science into the clinic!

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

Supriya Peshin Honored to be Selected as a Featured Voice for ASCO Annual Meeting 2025 - OncoDaily Supriya Peshin Honored to be Selected as a Featured Voice for ASCO Annual Meeting 2025 / ASCO, ASCO 2025, ASCO Annual Meeting 2025, ASCO25, cancer, OncoDaily,

Supriya Peshin Honored to be Selected as a Featured Voice for ASCO Annual Meeting 2025
@supriyapeshin.bsky.social @ascocancer.bsky.social

oncodaily.com/insight/supr...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO25

Honored to be part of it . Thank you @ascocancer.bsky.social for giving me this opportunity

A comprehensive review of #pancsm in
@thelancet.bsky.social

Underscores current 🚧
🌟 Discusses future promise 🌟
Emphasizes need for #novel 🎯

🔗: thelancet.com/journals/lan... #GIonc

@biagioricciutimd.bsky.social
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@kjankovic.bsky.social

Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study - PubMed Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no...

Publication alert ‼️ 🔔Large retrospective analysis of 153 #PCL patients using new definition of ≥ 5% circulating plasma cells finds secondary PCL associated with a worse prognosis, with median OS of 3.2 months vs 36.6 months for primary PCL: pubmed.ncbi.nlm.nih.gov/40241568/@oncodaily.bsky.social

Touching on 2nd opinions, scanxiety, communication styles and cultural sensitivity - Lung Cancer Europe - OncoDaily Touching on 2nd opinions, scanxiety, communication styles and cultural sensitivity - Lung Cancer Europe / cancer, Eric Singhi, IASLC, Lung cancer, Lung Cancer

LuCE - Touching on 2nd opinions, scanxiety, communication styles and cultural sensitivity

@lungcancereurope.bsky.social @iaslc.bsky.social
@narjustflorezmd.bsky.social @lungoncdoc.bsky.social

oncodaily.com/blog/lung-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Nothing gives me a boost like meeting with my @pallonccop.bsky.social family. Combine that with my love of #nerdy 🤓 and this is going to be a dynamite collaboration. Make sure you don't miss out next week. Join us! #hpm #hapc #pallonc #supponc #AI #healthIT #oncsky #medsky

Finally getting some spring weather in the #Midwest 🌞🌞🌹🥀🌻 on #BowTieFriday. Looking forward to #ASCO25 with abstract release this week. What are you looking forward to?

@docwithbowtie.bsky.social
@engagetheo.bsky.social
@djweiner.bsky.social
@stephjantzen.bsky.social
@zachradcliffphd.bsky.social

ICYMI: Small studies in prostate cancer suggest that intermittent androgen deprivation therapy or treatment breaks may be an option for certain patients. Drs. Jordan Ciuro, Mehmet Asim Bilen, and Shahid Ahmed discuss de-escalation decisions for #ASCODailyNews: brnw.ch/21wS0JZ

Your research could impact the quality of life of a peer or patient. Share your insights or data-driven solutions with an audience that shares your passion for high-quality oncology care and workplace health.

Submit your abstract to #ASCOQLTY25 today: brnw.ch/21wS21S